Global VNA market to touch $335M by 2018

The global market for Vendor Neutral Archives (VNA) is estimated to have a global market of $163.6 million in 2013 and projected to reach $335.4 million by 2018, according to a MarketsandMarkets report published in October.

The report also outlines the PACS global market and provides a comparative analysis of the two healthcare information systems, with the VNA in an exponential stage where the PACS market was about 10 to 15 years ago. PACs, meanwhile, is described as a mature market in which market players are attempting to invest in product differentiations and looking for new customer groups.

VNAs are being propelled into the global market because of their advantages over PACS such as interoperability, flexibility, and accessibility. Obstacles for growth include increasing incidences of data breaches, VNA’s complexity, lack of industry-accepted VNA definitions, and long VNA lifecycles.

The market is divided by delivery mode, according to MarketsandMarkets, with categorizations of on-premise VNAs, hybrid VNAs, and fully cloud-hosted VNAs. Hybrid VNAs are predicted to grow at a faster rate than on-premise, though on-premise dominate the market for total revenue contribution. Hybrid VNAs are forecasted to have a global market of $51.3 million by 2018.

North America is the largest contributor to this market and is valued at $140.3 million in 2013. Instatement of policy such as the HITECH (Healthcare Insurance Portability and Accountability) act and the Affordable Care Act will likely bring about growing adoptions of EHRs and VNAs and hospital consolidations in the U.S. market.

“With this, the market is all set to witness trends such as integration of VNAs with EHRs, employment of cloud computing solutions for VNA products, and a holistic approach for delivering enhanced patient care,” read the executive summary.

Major players in this global market are Acuo Technologies (U.S.), Agfa HealthCare (Belgium), BridgeHead Software (U.K.), Carestream Health (U.S.), Dell, Inc. (U.S.), GE Healthcare (U.K.), Fujifilm Corporation (Japan), Merge Health (U.S.), McKesson Corporation (U.S.), Philips Healthcare (The Netherlands), Siemens Healthcare (Germany), and TeraMedica (U.S.), according to the report.

Around the web

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease. 

CCTA is being utilized more and more for the diagnosis and management of suspected coronary artery disease. An international group of specialists shared their perspective on this ongoing trend.

The new technology shows early potential to make a significant impact on imaging workflows and patient care.